Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of single doses of Stalevo [levodopa/carbidopa/entacapone] 200 and levodopa/carbidopa 200/50mg on striatal 11C-raclopride binding potential in Parkinson's disease patients with wearing-off symptoms; an open, randomised, active-controlled,two-period crossover study

Next Previous
X
Search
Trial Profile

Effects of single doses of Stalevo [levodopa/carbidopa/entacapone] 200 and levodopa/carbidopa 200/50mg on striatal 11C-raclopride binding potential in Parkinson's disease patients with wearing-off symptoms; an open, randomised, active-controlled,two-period crossover study

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa/entacapone (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Orion

    • Most Recent Events

    • 09 Oct 2009 Planned end date changed from 1 Jul 2008 to 1 May 2008 as reported by ClinicalTrials.gov.
    • 09 Oct 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Dec 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top